同和药业
(300636)
| 流通市值:22.04亿 | | | 总市值:25.20亿 |
| 流通股本:3.67亿 | | | 总股本:4.20亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 608,217,884.31 | 383,163,489.97 | 184,392,671.37 | 828,659,350.98 |
| 营业收入 | 608,217,884.31 | 383,163,489.97 | 184,392,671.37 | 828,659,350.98 |
| 二、营业总成本 | 562,366,220.33 | 357,376,905.98 | 167,876,632.18 | 702,520,673.31 |
| 营业成本 | 438,795,832.54 | 275,395,888.73 | 131,745,065.82 | 577,933,442.86 |
| 税金及附加 | 6,875,702.33 | 4,399,014.99 | 1,378,782.78 | 6,496,304.8 |
| 销售费用 | 20,763,127.57 | 14,049,425.13 | 6,186,641.62 | 28,918,363.5 |
| 管理费用 | 32,909,499.58 | 21,582,282.11 | 9,863,739.24 | 37,779,917.42 |
| 研发费用 | 54,270,578.41 | 35,962,653 | 15,512,609.13 | 64,993,391.22 |
| 财务费用 | 8,751,479.9 | 5,987,642.02 | 3,189,793.59 | -13,600,746.49 |
| 其中:利息费用 | 6,363,392.94 | 4,905,128.48 | 2,326,673.43 | 12,498,497.27 |
| 其中:利息收入 | 10,890,341.34 | 8,884,379.54 | - | 25,522,287.79 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 539,726.18 | 191,063.33 | 131,150 | 214,316.67 |
| 加:投资收益 | -2,618,060.14 | -1,958,844.06 | -452,504.61 | -1,116,706.88 |
| 资产处置收益 | -63,554.06 | -63,554.06 | 67,081.06 | -767,628.83 |
| 资产减值损失(新) | -16,356,549.01 | -9,143,049.19 | -225,175.73 | -62,190,491.59 |
| 信用减值损失(新) | -2,079,237.17 | -607,784.46 | -453,372.53 | -1,464,805.35 |
| 其他收益 | 8,122,266.91 | 5,876,010.49 | 4,032,776.52 | 14,081,023.53 |
| 四、营业利润 | 33,396,256.69 | 20,080,426.04 | 19,615,993.9 | 74,894,385.22 |
| 加:营业外收入 | 532,140.8 | 500,523.56 | - | 682,342.22 |
| 减:营业外支出 | 5,076.13 | 3,093.3 | - | - |
| 五、利润总额 | 33,923,321.36 | 20,577,856.3 | 19,615,993.9 | 75,576,727.44 |
| 减:所得税费用 | -4,533,961.5 | -3,993,126.33 | 836,491.19 | 2,485,294.13 |
| 六、净利润 | 38,457,282.86 | 24,570,982.63 | 18,779,502.71 | 73,091,433.31 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 38,457,282.86 | 24,570,982.63 | 18,779,502.71 | 73,091,433.31 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 38,457,282.86 | 24,570,982.63 | 18,779,502.71 | 73,091,433.31 |
| 扣除非经常损益后的净利润 | 31,666,450.45 | 19,926,972.08 | 16,064,332.56 | 62,744,675.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.06 | 0.04 | 0.17 |
| (二)稀释每股收益 | 0.09 | 0.06 | 0.04 | 0.17 |
| 九、综合收益总额 | 38,457,282.86 | 24,570,982.63 | 18,779,502.71 | 73,091,433.31 |
| 归属于母公司股东的综合收益总额 | 38,457,282.86 | 24,570,982.63 | 18,779,502.71 | 73,091,433.31 |
| 公告日期 | 2026-10-29 | 2026-08-26 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |